2,903 press releases indexed under healthcare.
Continuous smartwatch monitoring shown to safely support post-surgical care, reducing disruptions for patients and easing nursing time for direct patient care SINGAPORE, July 14, 2026 /PRNewswire/ -- The National University Hospital (NUH) is set to expand the use of wearable technology...
Der Bericht hebt saubere Energie, Innovation und ESG-Anerkennung hervor ZIBO, China, 15. Juli 2026 /PRNewswire/ -- INTCO Medical („das Unternehmen"), ein weltweit führender Hersteller von Einweghandschuhen, hat seinen ESG-Bericht (Umwelt, Soziales und Unternehmensführung) für 2025...
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN. 1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the US FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic s
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.
This Gorgeous Grandma Day, Lake Park Dental in Milwaukee spotlights how modern, metal-free implants help women 55 and up smile with confidence again. The post Lake Park Dental Celebrates Gorgeous Grandma Day With a Toast to Milwaukee Smiles first appeared on
MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 by the Royal Bank of Canada (the “ Applicant ”) in its capacity as a secured creditor (the “ CCAA Proceedings ”) and the Court-approved restructuring transaction announced on July 3, 2026, Polar Valley Investments Limited (“ Polar ”) has successfully closed the acquisition of all of the equity interests in three affiliates of the Company, namely Solutions Staffing Inc. (“ SSI ”), Canadian Health Care Agency Ltd. (“ CHCA ”) and Premier Soin Nordik Inc. / Premier Health Nordik Inc. (“ Nordik Québec ”) (the “ Transaction ”).
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten...
As consumers look beyond demanding daily hair and skincare regimens, this QUINT review explores why Q.SCALP and Q.FACE are attracting attention, how the brand positions its once-monthly exosome-serum systems, and what buyers should confirm about pricing, subscriptions, FDA status, and guarantee terms before ordering.
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Crescent from the offering
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a...
HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9...